Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,417
datasets available to search
ShareScore release 0.9.0
Dataset results
1,417 results for “triple negative breast cancer”
Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer
ClinicalTrials.gov study NCT03106077. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer
ClinicalTrials.gov study NCT02971761. IPD Sharing: Not stated. Countries: 1. Publications: 0.
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
ClinicalTrials.gov study NCT03387085. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
ClinicalTrials.gov study NCT02368691. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer
ClinicalTrials.gov study NCT01207102. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
ClinicalTrials.gov study NCT02720185. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
ClinicalTrials.gov study NCT02788981. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
ClinicalTrials.gov study NCT04837209. IPD Sharing: YES. Countries: 1. Publications: 0.
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chem
ClinicalTrials.gov study NCT02411656. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
ClinicalTrials.gov study NCT03199040. IPD Sharing: NO. Countries: 1. Publications: 0.
Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer
ClinicalTrials.gov study NCT02521363. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
ClinicalTrials.gov study NCT03945721. IPD Sharing: YES. Countries: 1. Publications: 0.
Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer
ClinicalTrials.gov study NCT04494958. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
ClinicalTrials.gov study NCT05460273. IPD Sharing: YES. Countries: 1. Publications: 0.
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
ClinicalTrials.gov study NCT04331067. IPD Sharing: NO. Countries: 1. Publications: 0.
A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer
ClinicalTrials.gov study NCT00674206. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
ClinicalTrials.gov study NCT01272141. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
ClinicalTrials.gov study NCT02768701. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
ClinicalTrials.gov study NCT04216472. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
ClinicalTrials.gov study NCT03414684. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.